Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...

The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.

Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google ...

We recently compiled a list of the 10 AI News You Should Not Miss. In this article, we are going to take a look at where ...

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trials of drugs designed using AI to start late this year.

Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma partnerships with Eli ...

Among the most important aspects of this story is AlphaFold, the artificial intelligence and foundation model platform developed by Google DeepMind and Isomorphic Labs, both Alphabet companies.

Isomorphic Labs launches into an already well-populated drug discovery category, with many large drugmakers exploring the technology along with a host of specialist players like Exscientia ...

The pharma giant is partnering with software firms to imagine new drugs, find targets, and design clinical trials ...

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.